Through our partnerships, we are helping translate world-class, clinical research into potential patient solutions that may change the course of kidney care.
Collaborator Case Study Example:
University of Michigan
University of Michigan has multiple and advanced biomarker hypotheses to better serve the kidney disease patient population but needs a partner with business expertise and processes to help bring it to market.
A new biomarker – uEGF – is being studied at all stages of chronic kidney disease (CKD), even pre-CKD. Will it be highly prognostic in early-stage, chronic kidney disease, allowing for improved kidney health outcomes?
The National Kidney Foundation, the largest, patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S, needed additional partners to further its efforts in improving outcomes and quality of life.
Renalytix and National Kidney Foundation will work together to improve kidney disease diagnosis and early-stage, risk assessment through new and enhanced physician education.
Renalytix needs distinguished and expert support in identifying exactly what and where the barriers are to optimal kidney health management.
As a leader in health-related behavioral economics, VAL Health will provide Renalytix with the strategic research to help unearth those targeted behavioral changes needed to engage both doctors and patients in the best kidney health care management.
Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.